A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study of the Safety and Efficacy of 2 Doses of Tigecycline Versus Imipenem/Cilastatin for the Treatment of Subjects With Hospital-Acquired Pneumonia.

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study of the Safety and Efficacy of 2 Doses of Tigecycline Versus Imipenem/Cilastatin for the Treatment of Subjects With Hospital-Acquired Pneumonia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2013

At a glance

  • Drugs Tigecycline (Primary) ; Imipenem/cilastatin
  • Indications Nosocomial pneumonia; Pseudomonal infections; Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2012 Results presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases.
    • 11 Aug 2011 Planned end date changed from Jan 2013 to Jun 2011 as reported by ClinicalTrials.gov.
    • 11 Aug 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top